Targeting triple-negative breast cancer: optimising therapeutic outcomes
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting triple-negative breast cancer: optimising therapeutic outcomes
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue 9, Pages 2223-2234
Publisher
Oxford University Press (OUP)
Online
2012-04-20
DOI
10.1093/annonc/mds067
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer
- (2017) L. A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.
- (2017) S. Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
- (2017) A. R. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).
- (2017) J. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
- (2017) R. A. Dent et al. JOURNAL OF CLINICAL ONCOLOGY
- Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT).
- (2017) F. Cuppone et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).
- (2017) E. P. Hamilton et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.
- (2017) G. Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).
- (2017) J. Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV).
- (2017) C. Hudis et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.
- (2017) H. D. Bear et al. JOURNAL OF CLINICAL ONCOLOGY
- Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).
- (2017) A. M. Gonzalez-Angulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
- (2011) K. D. Miller et al. ANNALS OF ONCOLOGY
- Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
- (2011) Mogens Bernsdorf et al. BREAST CANCER RESEARCH AND TREATMENT
- Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women
- (2011) E. Comen et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract P1-11-07: Results of a Phase II Study of Neoadjuvant Platinum/Taxane Based Chemotherapy and Erlotinib for Triple Negative Breast Cancer
- (2011) P Sharma et al. CANCER RESEARCH
- Abstract P2-16-01: Overall Survival Data from SOLTI-0701: A Multinational, Double-Blind, Placebo-Controlled, Randomized Phase 2b Study Evaluating the Oral Combination of Sorafenib and Capecitabine in Patients with Locally Advanced or Metastatic HER2-Negative Breast Cancer
- (2011) P Gomez et al. CANCER RESEARCH
- Abstract P2-16-03: Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial
- (2011) S Bondarde et al. CANCER RESEARCH
- Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC)
- (2011) J O'Shaughnessy et al. CANCER RESEARCH
- Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer
- (2011) G Curigliano et al. CANCER RESEARCH
- Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial:
- (2011) J Baselga et al. CANCER RESEARCH
- Abstract PD01-07: Transcriptome Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological Subgroups and Reveals Therapeutic Strategies
- (2011) BD Lehmann et al. CANCER RESEARCH
- Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
- (2011) A. M. Jubb et al. CLINICAL CANCER RESEARCH
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Avastin Hearing Leads to More Uncertainty Over Drug's Future
- (2011) M. Goozner JNCI-Journal of the National Cancer Institute
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Stratification of Triple-Negative Breast Cancers
- (2011) C. M. Perou ONCOLOGIST
- SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
- (2010) E. L. Mayer et al. ANNALS OF ONCOLOGY
- Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer
- (2010) X. S. Chen et al. ANNALS OF ONCOLOGY
- Triple negative breast cancer: unmet medical needs
- (2010) Sumanta Kumar Pal et al. BREAST CANCER RESEARCH AND TREATMENT
- Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
- (2010) H. Wildiers et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
- (2010) J. Baselga et al. CANCER RESEARCH
- Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.
- (2010) L. Carey et al. CANCER RESEARCH
- Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
- (2010) J. O'Shaughnessy et al. CANCER RESEARCH
- Characteristics of triple-negative breast cancer
- (2010) Tim C. de Ruijter et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Deconstructing the molecular portraits of breast cancer
- (2010) Aleix Prat et al. Molecular Oncology
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
- (2009) G. Frasci et al. ANNALS OF ONCOLOGY
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
- (2009) Giulia Bianchi et al. ANTI-CANCER DRUGS
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
- (2009) Farrah Kassam et al. Clinical Breast Cancer
- Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?
- (2009) Rachel E. Sanborn CURRENT TREATMENT OPTIONS IN ONCOLOGY
- 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative
- (2009) G.S. Bhattacharyya et al. EJC SUPPLEMENTS
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases
- (2009) Florian Heitz et al. EUROPEAN JOURNAL OF CANCER
- Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?
- (2009) Fang-Zhen Shen et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction
- (2009) Patrick G. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
- (2009) Judith Hugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
- (2008) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
- (2008) Giuseppe Viale et al. BREAST CANCER RESEARCH AND TREATMENT
- Subtypes of Breast Cancer Show Preferential Site of Relapse
- (2008) M. Smid et al. CANCER RESEARCH
- Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer
- (2008) David Loesch et al. Clinical Breast Cancer
- How basal are triple-negative breast cancers?
- (2008) François Bertucci et al. INTERNATIONAL JOURNAL OF CANCER
- Basal-like subtype and BRCA1 dysfunction in breast cancers
- (2008) Yasuo Miyoshi et al. International Journal of Clinical Oncology
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
- (2008) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
- (2008) Alvaro Moreno-Aspitia et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started